Investing
50 Mid-Cap and Larger Stocks More Than Doubled in 2017
Published:
Last Updated:
With 2017 nearing an end, it is important to consider just what has happened. Tax reform looks very likely now, and gross domestic product is higher in the United States and abroad. Despite a Federal Reserve that looks poised to raise interest rates, there is an expectation of higher global growth and recovery trends to continue well into 2018.
If you include dividends, the top exchange traded funds tracking the major U.S. indexes have rallied handily in 2017. And that is already with an eight-year bull market. The gains so far in 2017 were last seen at over 24% on the Dow Jones Industrial Average and over 19% on the S&P 500 Index. The Nasdaq-100 Index was last seen up 33%.
It would be easy to get the pom-poms and cheer the bull market on, but there are many other key stocks that have more than doubled in 2017.
24/7 Wall St. has screened 50 stocks that have risen 100% or more (some far more) in 2017. Using performance and valuation metrics from Finviz, we tracked the U.S.-based companies that had market capitalizations of $2 billion and higher. We looked at the forward price-to-earnings (P/E) ratio and the dividend (if any). We also looked at the consensus analyst price target data from Thomson Reuters, if applicable.
AnaptysBio Inc. (NASDAQ: ANAB) is the top performer of the lot with a gain of over 400%. With its shares close to $94, some analysts have opined recently that its shares could go even higher. SunTrust has a $115 target and Jefferies has a $101 target.
Nektar Therapeutics (NASDAQ: NKTR) was up well over 300% so far in 2017, but at $57.68 a share it is well above the consensus analyst price target.
Weight Watchers International Inc. (NYSE: WTW) was last seen up almost 300% so far in 2017, aided by Oprah, of course. The stock actually has been range bound for the past few months, and the diet and lifestyle company now has a market cap of almost $3 billion.
Exact Sciences Corp. (NASDAQ: EXAS) was last seen up 280% or so in 2017, and the $51.68 share price is right in line with a $58.60 consensus price target.
Scientific Games Corp. (NASDAQ: SGMS) was last seen up more than 260% so far in 2017, but with shares up at $51.80 the consensus price target is down at $46.00.
Some companies see great gains because of mergers and others because of their own news. Keep in mind that there are no assurances at all that companies will rise more than 100% (and exponentially) again the following year. Many of them even may see more than all their good news having been priced in.
Below is a table below showing all 50 stocks with gains of 100% to 400%.
| Company | Ticker | Market Cap | Fwd P/E | Dividend | Perf YTD | Price |
| AnaptysBio | ANAB | 2.07B | – | – | 440.94% | $ 93.76 |
| Straight Path Communications | STRP | 2.32B | – | – | 434.65% | $ 181.81 |
| Nektar Therapeutics | NKTR | 8.90B | – | – | 363.73% | $ 57.57 |
| Weight Watchers International | WTW | 2.92B | 25.16 | – | 295.98% | $ 45.81 |
| Exact Sciences | EXAS | 6.13B | – | – | 285.93% | $ 51.95 |
| Scientific Games | SGMS | 4.59B | – | – | 263.21% | $ 51.70 |
| LendingTree | TREE | 4.00B | 66.67 | – | 239.76% | $ 347.35 |
| Alnylam Pharmaceuticals | ALNY | 12.16B | – | – | 235.44% | $ 124.58 |
| Foundation Medicine | FMI | 2.15B | – | – | 230.23% | $ 59.35 |
| RH | RH | 2.10B | 19.76 | – | 224.53% | $ 100.19 |
| Puma Biotechnology | PBYI | 3.74B | – | – | 219.87% | $ 99.75 |
| Sage Therapeutics | SAGE | 6.49B | – | – | 217.90% | $ 164.50 |
| Universal Display | OLED | 8.02B | 53.56 | 0.07% | 202.93% | $ 176.30 |
| Bluebird Bio | BLUE | 8.45B | – | – | 196.52% | $ 183.25 |
| Square | SQ | 14.38B | 82.29 | – | 171.68% | $ 37.88 |
| Blueprint Medicines | BPMC | 2.95B | – | – | 167.84% | $ 75.66 |
| Amicus Therapeutics | FOLD | 2.14B | – | – | 158.55% | $ 13.08 |
| Green Dot | GDOT | 3.01B | 24.16 | – | 156.31% | $ 60.88 |
| TAL Education Group | TAL | 14.61B | 54.29 | – | 154.54% | $ 29.99 |
| Triton International | TRTN | 3.09B | 10.44 | 4.55% | 153.99% | $ 39.77 |
| Kirkland Lake Gold | KL | 2.75B | – | 0.23% | 151.80% | $ 13.50 |
| Loxo Oncology | LOXO | 2.48B | – | – | 145.90% | $ 79.68 |
| Shopify | SHOP | 10.25B | 400.08 | – | 145.44% | $ 106.85 |
| Align Technology | ALGN | 18.74B | 52.78 | – | 142.95% | $ 234.40 |
| Autohome | ATHM | 7.15B | 20.85 | – | 142.21% | $ 60.53 |
| Arista Networks | ANET | 16.57B | 37.47 | – | 138.74% | $ 233.54 |
| RingCentral | RNG | 3.68B | 174.82 | – | 137.62% | $ 49.65 |
| Juno Therapeutics | JUNO | 5.04B | – | – | 137.03% | $ 43.50 |
| Insmed | INSM | 2.36B | – | – | 128.87% | $ 30.05 |
| Wayfair | W | 6.69B | – | – | 126.13% | $ 79.44 |
| Take-Two Interactive Software | TTWO | 12.43B | 23.35 | – | 125.58% | $ 111.97 |
| NRG Energy | NRG | 8.76B | 12.69 | 0.44% | 124.31% | $ 27.58 |
| Roku | ROKU | 4.51B | – | – | 122.60% | $ 54.90 |
| Teladoc | TDOC | 2.03B | – | – | 117.88% | $ 36.00 |
| Chemours | CC | 8.91B | 9.51 | 1.42% | 117.47% | $ 48.40 |
| 2U | TWOU | 3.28B | – | – | 117.28% | $ 66.43 |
| Penn National Gaming | PENN | 2.66B | 23.47 | – | 115.30% | $ 28.78 |
| First Solar | FSLR | 7.09B | 46.78 | – | 114.90% | $ 70.03 |
| Kronos Worldwide | KRO | 2.90B | 12.47 | 2.36% | 112.73% | $ 25.86 |
| New Relic | NEWR | 3.24B | 267.62 | – | 111.26% | $ 60.43 |
| IPG Photonics | IPGP | 11.06B | 27.03 | – | 110.78% | $ 211.14 |
| Coherent | COHR | 7.09B | 16.09 | – | 109.65% | $ 291.80 |
| Portola Pharmaceuticals | PTLA | 3.10B | – | – | 109.54% | $ 47.66 |
| Rogers | ROG | 2.92B | 25.92 | – | 109.43% | $ 163.04 |
| AveXis | AVXS | 3.16B | – | – | 107.25% | $ 99.75 |
| SiteOne Landscape Supply | SITE | 2.86B | 40.26 | – | 106.80% | $ 72.00 |
| National Beverage | FIZZ | 4.89B | 29.45 | – | 105.26% | $ 104.50 |
| NVR | NVR | 12.74B | 20.11 | – | 103.63% | $ 3,411.23 |
| Myriad Genetics | MYGN | 2.29B | 27.5 | – | 100.78% | $ 33.73 |
| Halozyme Therapeutics | HALO | 2.91B | – | – | 100.10% | $ 19.77 |
“The Next NVIDIA” Could Change Your Life
If you missed out on NVIDIA’s historic run, your chance to see life-changing profits from AI isn’t over.
The 24/7 Wall Street Analyst who first called NVIDIA’s AI-fueled rise in 2009 just published a brand-new research report named “The Next NVIDIA.”
Click here to download your FREE copy.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
